Drug · CHEMBL39

SEROTONIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. SEROTONIN. Drugs and targets, record CHEMBL39. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL39

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: SEROTONIN; ChEMBL
ChEMBL ID: CHEMBL39; ChEMBL
Type: Small molecule; ChEMBL
Other names: 5-ht, 5-hydroxytryptamine, Enteramine, Thrombotonin; ChEMBL
DrugBank: DB08839; DrugBank
InChIKey: QZAYGJVTTNCVMB-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases18

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
major depressive disorder	Phase 3	ClinicalTrials.gov	40	40	https://conductscience.org/library/drugs?q=MONDO_0002009
depressive disorder	Phase 3	ClinicalTrials.gov	15	15	https://conductscience.org/library/drugs?q=MONDO_0002050
obsessive-compulsive disorder	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0008114
post-traumatic stress disorder	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005146
Mental deterioration	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0001268
amyotrophic lateral sclerosis	Early phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0004976
anxiety	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0011918
anxiety disorder	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005618
bipolar disorder	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0004985
fibromyalgia	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005546

1 to 10 of 18Source Open Targets

See all 18 diseases

Trials10

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 10 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 79 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01299272	A Study in Prevention of Re-emergence of Depression Symptoms	Phase 3	1,249	2018-04-17	selective serotonin reuptake inhibitors	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT00474708	Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients	Phase 4	1,151	2010-04-30	selective serotonin reuptake inhibitors	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT00789854	Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients	Phase 3	688	2012-05-23	selective serotonin reuptake inhibitor	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01811147	Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI	Phase 4	192	2019-12-02	selective serotonin reuptake inhibitor	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT03222570	An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression	Phase 2	90	2025-07-02	selective serotonin reuptake inhibitor	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT00129467	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care		47	2014-02-12	selective serotonin reuptake inhibitor	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01077596	Carcinogenicity Study of Bupropion		50,430	2011-02-10	selective serotonin reuptake inhibitors	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01001559	Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis		242	2013-12-19	selective serotonin reuptake inhibitor, serotonin and norepinephrine reuptake inhibitor	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT00095745	A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder	Phase 3	1,002		selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04975100	Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder	Phase 4	60		selective serotonin reuptake inhibitors	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL39

GET https://conductscience.org/api/drugs/v1/CHEMBL39/targets

API reference For AI assistants